Lead Product(s) : Deferoxamine Mesylate
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Approved
Sponsor : Mitem Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
MITEM Pharma Acquires DESFERAL® Rights Backed by TECHLIFE CAPITAL, MACSF
Details : Mitem acquires Desfera (deferoxamine mesylate) products from Novartis. It is indicated for treating iron overload, and forex, following blood transfusions necessary for treating beta-thalassemia.
Brand Name : Desfera
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 25, 2024
Lead Product(s) : Deferoxamine Mesylate
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Approved
Sponsor : Mitem Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Patiromer Sorbitex Calcium
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Approved
Sponsor : CSL Vifor
Deal Size : Not Applicable
Deal Type : Not Applicable
Veltassa® (patiromer) Approved in Japan For The Treatment of Adults with Hyperkalemia
Details : Veltassa (patiromer sorbitex calcium) is a potassium binder indicated for the treatment of hyperkalemia in adults and pediatric patients ages 12 years and older.
Brand Name : Veltassa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 23, 2024
Lead Product(s) : Patiromer Sorbitex Calcium
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Approved
Sponsor : CSL Vifor
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Selonabant
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Phase II
Sponsor : National Institutes of Health
Deal Size : $1.9 million
Deal Type : Funding
Anebulo Pharmaceuticals Awarded NIDA Grant for Acute Cannabis-Induced Toxic Effects
Details : The funding aims to support the development of ANEB-001 (selonabant) for the potential use as an emergency treatment of acute cannabis-induced toxicities, including cannabis-induced CNS depression.
Brand Name : ANEB-001
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 22, 2024
Lead Product(s) : Selonabant
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Phase II
Sponsor : National Institutes of Health
Deal Size : $1.9 million
Deal Type : Funding
Lead Product(s) : Glucarpidase
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Approved
Sponsor : SERB Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
M8 Pharmaceuticals Signs Exclusive Agreement with SERB to Bring Voraxaze® to Latin America
Details : M8 will register, market and commercialize SERB's supportive oncology product Voraxaze (glucarpidase), a carboxypeptidase that reduces toxic plasma methotrexate concentration, in Latin America.
Brand Name : Voraxaze
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 20, 2024
Lead Product(s) : Glucarpidase
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Approved
Sponsor : SERB Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Atropine,Pralidoxime Chloride
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Approved
Sponsor : ASPR
Deal Size : $9.9 million
Deal Type : Agreement
Details : Under the agreement, Meridian will supply DuoDote to the Administration for Strategic Preparedness and Response within the United States. DuoDote® is an FDA-approved dual-chamber autoinjector (atropine and pralidoxime chloride) chemical nerve agent anti...
Brand Name : DuoDote
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 14, 2023
Lead Product(s) : Atropine,Pralidoxime Chloride
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Approved
Sponsor : ASPR
Deal Size : $9.9 million
Deal Type : Agreement
Lead Product(s) : Edetate Calcium Disodium
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Edetate calcium disodium for injection is a prescription medicine, used for the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults.
Brand Name : Edetate Calcium Disodium-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 10, 2023
Lead Product(s) : Edetate Calcium Disodium
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ethanol
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Eton Pharmaceuticals Receives Complete Response Letter (CRL) for Dehydrated Alcohol Injection
Details : FDA issued a Complete Response Letter (CRL) in response to its New Drug Application (NDA) for dehydrated alcohol injection for the treatment of methanol poisoning.
Brand Name : Undsclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 28, 2023
Lead Product(s) : Ethanol
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : 3,4,3-Li(1,2-hopo)
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
SRI’s Radioactive Contamination Treatment Is Now in Its First-In-Human Trial
Details : HOPO 14-1 (3,4,3-Li(1,2-hopo) is a novel orally administered experimental drug, designed to act as a defence against radioactive threats and is being investigated to treat radioactive contamination in the body.
Brand Name : HOPO 14-1
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 15, 2023
Lead Product(s) : 3,4,3-Li(1,2-hopo)
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Atropine Sulfate,Scopolamine
Therapeutic Area : Pharmacology/Toxicology
Study Phase : IND Enabling
Sponsor : U.S. Defense Department
Deal Size : Undisclosed
Deal Type : Funding
Details : The funding will support the continued development of a promising medical countermeasure for nerve agents that contain a stable, fixed-dose combination formulation of atropine and scopolamine.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 06, 2022
Lead Product(s) : Atropine Sulfate,Scopolamine
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : IND Enabling
Sponsor : U.S. Defense Department
Deal Size : Undisclosed
Deal Type : Funding
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Undisclosed
Sponsor : U.S. Defense Department
Deal Size : Undisclosed
Deal Type : Funding
CMC Pharmaceuticals Awarded SBIR Grant for Concentrated Atropine Formulation
Details : The Phase I SBIR award will fund the formulation and analytical development of a concentrated Atropine Sulfate Drug Product with the aim to aid the military in treating organophosphate poisoning in service members.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 06, 2022
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Undisclosed
Sponsor : U.S. Defense Department
Deal Size : Undisclosed
Deal Type : Funding
LOOKING FOR A SUPPLIER?